Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial (Q41008161)
Jump to navigation
Jump to search
scientific article published on 21 December 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial |
scientific article published on 21 December 2015 |
Statements
1 reference
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial (English)
1 reference
Gérard Zalcman
Jacques Margery
Laurent Greillier
Olivier Molinier
Romain Corre
Isabelle Monnet
Valérie Gounant
Frédéric Rivière
Henri Janicot
Radj Gervais
Chrystèle Locher
Bernard Milleron
Quan Tran
Marie-Paule Lebitasy
Jean-Jacques Parienti
Arnaud Scherpereel
French Cooperative Thoracic Intergroup (IFCT)
Clarisse Audigier-Valette
21 December 2015
1 reference